Drugs / AV-MEL-1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03743298 | Apr 2021 → May 2024 | metastatic melanoma | Aivita Biomedical, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV-MEL-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03743298 ↗ |
| Modality | Cell therapy | “Autologous dendritic cells loaded with autologous tumor antigens (ATA)” NCT03743298 ↗ |
| Route | Other | “AV-MEL-1 injections will be given weekly for 3 weeks” NCT03743298 ↗ |